# Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
Canonical URL: https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-association-eha-annual-meeting
Ticker: IRON
Company: Disc Medicine
Source: Disc Medicine
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.discmedicine.com
## Summary

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use Updated data from the HELIOS open-label

## Article Body
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor use Updated data from the HELIOS open-label
## Recent Company News
- 2026-06-25 13:46 EST — [Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-positive-clinical-updates-at-the-2026-european-hematology-association-eha-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria](https://biopharmsignal.com/news/IRON/disc-medicine-provides-update-from-fda-type-a-meeting-for-bitopertin-in-erythropoietic-protoporphyria) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients](https://biopharmsignal.com/news/IRON/disc-medicine-launches-expanded-access-program-for-bitopertin-for-epp-patients) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://biopharmsignal.com/news/IRON/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting) — Source: Disc Medicine
- 2026-06-25 13:46 EST — [Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress](https://biopharmsignal.com/news/IRON/disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress) — Source: Disc Medicine
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)